ASO VISUAL ABSTRACT

ASO Visual Abstract: Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management

Giulio Ricotta, MD¹, Amandine Maulard, MD¹, Massimo Candiani, MD, PhD², Catherine Genestie, MD³, Patricia Pautier, MD⁴, Alexandra Leary, MD, PhD⁴, Cyrus Chargari, MD⁵, Giorgia Mangili, MD, PhD², Philippe Morice, MD, PhD^{1,6}, and Sébastien Gouy, MD, PhD¹

¹Department of Gynaecologic Surgery, Gustave-Roussy, Villejuif, France; ²IRCCS San Raffaele Hospital, Vita-Salute University, Milan, Italy; ³Department of Pathology, Gustave-Roussy, Villejuif, France; ⁴Medical Oncology, Gustave-Roussy, Villejuif, France; ⁵Radiation Oncology, Gustave-Roussy, Villejuif, France; ⁶Paris Sud University Kremlin-Bicêtre, Paris, France

As discussed in our article (<https://doi.org/10.1245/s10434-021-10776-7>), a clear cell borderline ovarian tumor is a rare entity, mainly unilateral and diagnosed at stage I disease. Peritoneal restaging surgery is not required for this stage

of malignancy. Synchronous endometrial disorders with atypia are infrequent, suggesting that systematic hysterectomy is not necessary.